KR20090121329A - 메탈로프로테아제 억제제로서 유용한 아릴-술폰아미드 구조를 갖는 화합물 - Google Patents

메탈로프로테아제 억제제로서 유용한 아릴-술폰아미드 구조를 갖는 화합물 Download PDF

Info

Publication number
KR20090121329A
KR20090121329A KR1020097019222A KR20097019222A KR20090121329A KR 20090121329 A KR20090121329 A KR 20090121329A KR 1020097019222 A KR1020097019222 A KR 1020097019222A KR 20097019222 A KR20097019222 A KR 20097019222A KR 20090121329 A KR20090121329 A KR 20090121329A
Authority
KR
South Korea
Prior art keywords
compound
group
formula
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097019222A
Other languages
English (en)
Korean (ko)
Inventor
아르만도 로셀로
엘리사 누티
엘리사베타 오르란디니
알도 발사모
티지아노 투치나르디
Original Assignee
브라코 이미징 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브라코 이미징 에스.피.에이. filed Critical 브라코 이미징 에스.피.에이.
Publication of KR20090121329A publication Critical patent/KR20090121329A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
KR1020097019222A 2007-03-19 2008-03-14 메탈로프로테아제 억제제로서 유용한 아릴-술폰아미드 구조를 갖는 화합물 Ceased KR20090121329A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104393A EP1972617A1 (en) 2007-03-19 2007-03-19 Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
EP07104393.9 2007-03-19

Publications (1)

Publication Number Publication Date
KR20090121329A true KR20090121329A (ko) 2009-11-25

Family

ID=38626433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097019222A Ceased KR20090121329A (ko) 2007-03-19 2008-03-14 메탈로프로테아제 억제제로서 유용한 아릴-술폰아미드 구조를 갖는 화합물

Country Status (12)

Country Link
US (1) US8329751B2 (cg-RX-API-DMAC10.html)
EP (2) EP1972617A1 (cg-RX-API-DMAC10.html)
JP (1) JP2010521529A (cg-RX-API-DMAC10.html)
KR (1) KR20090121329A (cg-RX-API-DMAC10.html)
CN (1) CN101610997A (cg-RX-API-DMAC10.html)
AU (1) AU2008228260B2 (cg-RX-API-DMAC10.html)
CA (1) CA2680239A1 (cg-RX-API-DMAC10.html)
IL (1) IL200951A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009009409A (cg-RX-API-DMAC10.html)
RU (1) RU2488580C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008113756A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200905263B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
WO2024102810A1 (en) 2022-11-08 2024-05-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5058026A (cg-RX-API-DMAC10.html) * 1973-09-26 1975-05-20
PL342009A1 (en) * 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
RU2217418C2 (ru) * 1998-04-03 2003-11-27 Санкио Компани, Лимитед Сульфонамидное производное, лекарственное средство, способы лечения
WO2006101828A1 (en) * 2005-03-15 2006-09-28 Bayer Cropscience Ag Insecticidal alkylamino phenyl sulfonamide derivatives

Also Published As

Publication number Publication date
MX2009009409A (es) 2009-09-14
JP2010521529A (ja) 2010-06-24
WO2008113756A8 (en) 2008-11-06
EP2121590A2 (en) 2009-11-25
US20100087505A1 (en) 2010-04-08
IL200951A0 (en) 2010-05-17
US8329751B2 (en) 2012-12-11
RU2488580C2 (ru) 2013-07-27
EP1972617A1 (en) 2008-09-24
AU2008228260A1 (en) 2008-09-25
AU2008228260B2 (en) 2012-11-22
WO2008113756A3 (en) 2008-12-18
RU2009138346A (ru) 2011-04-27
CA2680239A1 (en) 2008-09-25
WO2008113756A2 (en) 2008-09-25
ZA200905263B (en) 2010-06-30
CN101610997A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
US6518310B2 (en) Aminoguanidines and alkoxyguanidines as protease inhibitors
US6380258B2 (en) Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US20080242656A1 (en) N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof
MX2013003362A (es) Inhibidores de metaloproteinasa de matriz.
US20030065176A1 (en) Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
HUP0100277A2 (hu) 2,3,4,5-Tetrahidro-1H-[1,4]benzodiazepin-3-hidroxámsav-származékok mint metalloproteináz inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US6221914B1 (en) Sulfonamide bridging compounds that inhibit tryptase activity
ES2209244T3 (es) Inhibidores de las metaloproteasas de la matriz.
US8329751B2 (en) Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
US20120258960A1 (en) Novel multifunctional peptidase inhibitors, especially for medical use
CN101258132B (zh) 用作金属蛋白酶抑制剂的(2,5-二酮咪唑啉-1-基)-n-羟基-乙酰胺
US20110124653A1 (en) Aryl-sulphonamidic dimers as metalloproteases inhibitors
HK1115878B (en) (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
CZ309499A3 (cs) Sulfonylové sloučeniny dvojmocných arylových nebo heteroarylových hydroxamových kyselin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090915

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140626

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20141017

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140626

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I